Dr. Fuchs Discusses Immunotherapy in Gastric Cancer

Charles S. Fuchs, MD
Published Online: Tuesday, Jun 13, 2017



Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.

Better therapies are needed for patients with advanced gastric cancer, says Fuchs, and immunotherapy could be an option.

PD-L1 expression is seen in gastric cancer, suggesting that immunotherapy agents—such as pembrolizumab (Keytruda)—would be effective in this commonly occurring disease.
 


Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.

Better therapies are needed for patients with advanced gastric cancer, says Fuchs, and immunotherapy could be an option.

PD-L1 expression is seen in gastric cancer, suggesting that immunotherapy agents—such as pembrolizumab (Keytruda)—would be effective in this commonly occurring disease.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
$emailPop$